Treatment of a patient with classic Kaposi's sarcoma and chronic lymphocytic leukaemia with encapsulated liposomal doxorubicin

HAEMA

Volumn 7, Issue 2, 2004, Pages 231-232

  Danopoulou, Iphigenia ^a,b   Paparizos, Vassilis ^a   Stavrianeas, Nikolaos ^a   Georgala, Sofia ^a   Katsambas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

CLL; Encapsulated doxorubicin; Kaposi's sarcoma

Indexed keywords

ALPHA2B INTERFERON; CHLORAMBUCIL; CYTOSTATIC AGENT; DOXORUBICIN; PREDNISOLONE;

AGED; ARTICLE; BONE MARROW TOXICITY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; ENCAPSULATION; FEMALE; HEMATOCRIT; HUMAN; KAPOSI SARCOMA; LABORATORY TEST; LEUKOCYTE; PATIENT; RELAPSE; REMISSION; TREATMENT OUTCOME;

EID: 1842810227     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Dezube BJ. Acquired immunodeficiency syndrome-related Kaposi's sarcoma: clinical features, staging, and treatment. Semin Oncol 2000; 27: 424-430.
2. Gottlieb JJ, Washenic K, Chachoua A, Friedman-Kien A. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet 1997; 350: 1363-1364.
3. Richardson DS, Johnson SA. Anthracyclines in hematology: preclinical studies toxicity and delivery systems. Blood Rev 1997; 11: 201-223.
4. Berry G, Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9: 711-716.
5. Wollin U, Graef T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol 2001; 127: 128-134.